Retatrutide vs Tirzepatide
An approved drug against the unapproved one with bigger phase 2 numbers.
The distinction that mattersRetatrutide adds glucagon-receptor agonism on top of tirzepatide's two targets. It shows larger phase 2 weight loss but has no phase 3 safety data and no approval anywhere.
These are not equivalent in evidence Tirzepatide is rated 5/5 and Retatrutide is rated 3/5 — a gap of 2 levels on our scale. Similar marketing does not mean similar proof.
| Retatrutide In Clinical Trials | Tirzepatide FDA Approved | |
|---|---|---|
| Evidence rating |
3/5 Moderate
Evidence rating 3 out of 5: Moderate
|
5/5 Very strong
Evidence rating 5 out of 5: Very strong
|
| Regulatory status | Phase 3 (TRIUMPH program). Not approved anywhere. Widely and illegally sold grey-market. | FDA-approved for type 2 diabetes, chronic weight management, and obstructive sleep apnea in obesity |
| Category | Metabolic & Weight | Metabolic & Weight |
| Drug class | Triple GLP-1 / GIP / glucagon receptor agonist | Dual GIP / GLP-1 receptor agonist — 39-amino-acid acylated peptide |
| Route | Subcutaneous, once weekly (investigational) | Subcutaneous, once weekly |
| Half-life | ~6 days | ~5 days |
| Studied in | Phase 2 obesity and type 2 diabetes trials; phase 3 TRIUMPH trials ongoing across obesity, diabetes, knee osteoarthritis and sleep apnea. | SURPASS program (type 2 diabetes), SURMOUNT program (obesity, sleep apnea, heart failure), SURPASS-CVOT (cardiovascular outcomes). |
| Who should avoid it |
|
|
| Legal status | Investigational. Not approved by FDA, EMA, or any comparable regulator. Sale for human use is unlawful; "research chemical" labelling does not change that. | Prescription drug. FDA has stated tirzepatide is no longer in shortage, which sharply restricts lawful compounding. |
Benefits — Retatrutide
- Largest reported pharmacologic weight loss
Phase 2 data showed roughly 24% mean body-weight reduction at 48 weeks on the highest dose, with weight curves that had not yet plateaued.
- Marked hepatic fat reduction
A sub-study reported near-complete normalization of liver fat content in most participants with steatosis.
- Increased energy expenditure
The glucagon component adds a thermogenic mechanism absent from GLP-1-only drugs, in principle limiting metabolic adaptation.
Benefits — Tirzepatide
- Best-in-class weight reduction
SURMOUNT-1 reported roughly 21% mean body-weight reduction at 72 weeks on the 15 mg dose, with more than half of participants losing at least 20%.
- Superior HbA1c lowering
Reductions up to about 2.4 percentage points, and superiority over semaglutide 1 mg in the head-to-head SURPASS-2 trial.
- Treats obstructive sleep apnea
SURMOUNT-OSA showed large reductions in apnea-hypopnea index, leading to a specific FDA approval — the first drug approved for OSA.
- Favourable body-composition split
Sub-studies using imaging suggest a relatively high proportion of fat mass in total weight lost compared with diet alone, though lean loss still occurs.
- Blood pressure and lipid improvement
Consistent reductions in systolic blood pressure and triglycerides across the phase 3 program.
Risks & cons — Retatrutide
- No phase 3 safety data yet
Every claim about long-term safety is extrapolation. Approval is not guaranteed and prior obesity drugs have failed at exactly this stage.
- Dose-dependent heart-rate increase
Phase 2 showed increases in heart rate that peaked mid-trial. Cardiovascular outcome data do not yet exist.
- Glucose elevation potential
Glucagon agonism can raise hepatic glucose output; net glycemic effect depends on the balance with incretin activity.
- Severe GI effects at high doses
Nausea and vomiting were the dominant adverse events and drove discontinuations.
- Entirely unregulated supply
All retatrutide sold to consumers is illicit. There is no verified identity, purity, sterility, or dose accuracy, and no recourse if harmed.
Risks & cons — Tirzepatide
- Gastrointestinal side effects
Nausea, diarrhea, vomiting and constipation are dose-related and most common during escalation.
- Thyroid C-cell tumor boxed warning
Same rodent-derived contraindication as other incretin agonists: medullary thyroid carcinoma history or MEN2.
- Pancreatitis and gallbladder events
Uncommon but serious; rapid weight loss increases gallstone formation.
- Hypoglycemia in combination therapy
Risk rises substantially when added to sulfonylureas or insulin — those doses usually need reduction.
- Lean mass loss
As with all rapid weight-loss interventions, muscle is lost alongside fat without deliberate protein and resistance-training countermeasures.
A comparison is not a recommendation. Neither column is being suggested for you. Which — if either — is appropriate depends on your diagnosis, history and medications, and that is a conversation for a qualified clinician.